Get started
ESPERION THERAPEUTICS INC COM USD0.001ESPERION THERAPEUTICS INC COM USD0.001ESPERION THERAPEUTICS INC COM USD0.001

ESPERION THERAPEUTICS INC COM USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

0IIM chart


Full chart

0IIM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪474.85 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.620 USD
Net income (FY)
‪−209.25 M‬ USD
Revenue (FY)
‪116.33 M‬ USD
Shares float
‪195.06 M‬
Beta (1Y)
3.01

Employees


Employees (FY)
240
Change (1Y)
+41 +20.60%
Revenue / Employee (1Y)
‪484.73 K‬ USD
Net income / Employee (1Y)
‪−871.87 K‬ USD

About Esperion Therapeutics, Inc.


Sector
Health Technology
CEO
Sheldon L. Koenig
Headquarters
Ann Arbor
Website
esperion.com
Founded
1998
FIGI
BBG00JVRNKF8
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0IIM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

0IIM highest yielding bonds


PFE5307022
Esperion Therapeutics, Inc. 4.0% 15-NOV-2025
Yield to maturity
8.08%
Maturity date
Nov 15, 2025

Explore more bonds 

Frequently Asked Questions


The current price of 0IIM is 2.375 USD — it hasn't changed in the past 24 hours. Watch ESPERION THERAPEUTICS INC COM USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ESPERION THERAPEUTICS INC COM USD0.001 stocks are traded under the ticker 0IIM.
0IIM stock has fallen by −2.69% compared to the previous week, the month change is a 14.60% rise, over the last year ESPERION THERAPEUTICS INC COM USD0.001 has showed a 87.75% increase.
We've gathered analysts' opinions on ESPERION THERAPEUTICS INC COM USD0.001 future price: according to them, 0IIM price has a max estimate of 16.00 USD and a min estimate of 2.05 USD. Watch 0IIM chart and read a more detailed ESPERION THERAPEUTICS INC COM USD0.001 stock forecast: see what analysts think of ESPERION THERAPEUTICS INC COM USD0.001 and suggest that you do with its stocks.
0IIM reached its all-time high on Jan 24, 2018 with the price of 80.760 USD, and its all-time low was 0.741 USD and was reached on Oct 26, 2023. View more price dynamics on 0IIM chart.
See other stocks reaching their highest and lowest prices.
0IIM stock is 1.94% volatile and has beta coefficient of 3.01. Track ESPERION THERAPEUTICS INC COM USD0.001 stock price on the chart and check out the list of the most volatile stocks — is ESPERION THERAPEUTICS INC COM USD0.001 there?
Today ESPERION THERAPEUTICS INC COM USD0.001 has the market capitalization of ‪474.85 M‬, it has increased by 14.76% over the last week.
Yes, you can track ESPERION THERAPEUTICS INC COM USD0.001 financials in yearly and quarterly reports right on TradingView.
ESPERION THERAPEUTICS INC COM USD0.001 is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0IIM earnings for the last quarter are −0.15 USD per share, whereas the estimation was −0.18 USD resulting in a 14.42% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about ESPERION THERAPEUTICS INC COM USD0.001 earnings.
ESPERION THERAPEUTICS INC COM USD0.001 revenue for the last quarter amounts to ‪51.63 M‬ USD, despite the estimated figure of ‪51.31 M‬ USD. In the next quarter, revenue is expected to reach ‪60.94 M‬ USD.
0IIM net income for the last quarter is ‪−29.52 M‬ USD, while the quarter before that showed ‪−61.92 M‬ USD of net income which accounts for 52.32% change. Track more ESPERION THERAPEUTICS INC COM USD0.001 financial stats to get the full picture.
No, 0IIM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 240.00 employees. See our rating of the largest employees — is ESPERION THERAPEUTICS INC COM USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ESPERION THERAPEUTICS INC COM USD0.001 EBITDA is ‪29.60 M‬ USD, and current EBITDA margin is −133.58%. See more stats in ESPERION THERAPEUTICS INC COM USD0.001 financial statements.
Like other stocks, 0IIM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ESPERION THERAPEUTICS INC COM USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ESPERION THERAPEUTICS INC COM USD0.001 technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ESPERION THERAPEUTICS INC COM USD0.001 stock shows the neutral signal. See more of ESPERION THERAPEUTICS INC COM USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.